Dyne Therapeutics to Present at October Investor Conferences
September 28, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
September 20, 2023 16:05 ET
|
Dyne Therapeutics, Inc.
- On Track to Report Initial Data from the Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in the Second Half of 2023 - WALTHAM, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Dyne...
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
- On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 - WALTHAM, Mass., Aug. 03, 2023 (GLOBE...
Dyne Therapeutics to Present at Jefferies Healthcare Conference
June 01, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
May 25, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
- Initial Data from Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in Myotonic Dystrophy Type 1 Anticipated in the Second Half of 2023 - WALTHAM, Mass., May 25, 2023 (GLOBE...
Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
May 17, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
- Broad Distribution in CNS Demonstrated in Non-Human Primates - - Achieved Reduction of Toxic Nuclear DMPK RNA and Foci in the Brain in a DM1 Disease Model - WALTHAM, Mass., May 17, 2023 (GLOBE...
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 11, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
- On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 - WALTHAM, Mass., May 11, 2023 (GLOBE...
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
May 03, 2023 07:35 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
May 02, 2023 16:46 ET
|
Dyne Therapeutics, Inc.
- FORCE Delivers to CNS in Non-Human Primates -- FORCE Achieves Robust Reduction of Toxic Nuclear DMPK RNA and Foci in Brain of a DM1 Disease Model - WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE)...